Fractal fronts of diffusion in microgravity

Spatial scale invariance represents a remarkable feature of natural phenomena. A ubiquitous example is represented by miscible liquid phases undergoing diffusion. Theory and simulations predict that in the absence of gravity diffusion is characterized by long-ranged algebraic correlations. Experimental evidence of scale invariance generated by diffusion has been limited, because on Earth the development of long-range correlations is suppressed by gravity. Here we report experimental results obtained in microgravity during the flight of the FOTON M3 satellite. We find that during a diffusion process a dilute polymer solution exhibits scale-invariant concentration fluctuations with sizes ranging up to millimetres, and relaxation times as large as 1,000 s. The scale invariance is limited only by the finite size of the sample, in agreement with recent theoretical predictions. The presence of such fluctuations could possibly impact the growth of materials in microgravity

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic cancer (P = 0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events

The fractionation of paraffin wax mixtures.

IngenieursweseProsesingenieurswesePlease help us populate SUNScholar with the post print version of this article. It can be e-mailed to: [email protected]